HumeCare+ Tirzepatide Review: $199/Month, But It Is a Microdose Program (2026)

HumeCare+ charges $199 a month, billed monthly with no minimum term, and that covers the medication, the clinical visits, the coaching and its body-composition tracking. The catch is not the price — it is what the price buys: the program HumeCare publishes is Microdose GLP-1Rx, which in its own words "uses smaller doses of GLP-1 medication". Prices verified on HumeCare's own program page on August 28, 2026. HumeCare is an affiliate partner: we earn a commission if you start care through our links, at no extra cost to you — see our disclosure.

Microdosing is a different product, not a cheaper one

This is the fact to carry into any price comparison. A $199 microdose program and a $199 standard-dose program are not the same purchase, and the difference is not marketing.

The tirzepatide results people cite come from standard therapeutic doses. In the 72-week SURMOUNT-1 trial, adults without diabetes lost on average roughly 15% to 21% of body weight across the 5–15 mg doses, against about 3% on placebo¹; against semaglutide in SURMOUNT-5, tirzepatide produced roughly 20% versus 14%². Those are the numbers the whole category advertises against, and they were produced by the brand molecule at those doses. A protocol built on smaller doses has not been shown to produce them, and HumeCare does not claim it does.

To its credit, HumeCare publishes its own outcome beside the pitch rather than only the trial figures: a footnote states the data is self-reported from 1,185 HumeCare Med users and that average weight loss was 13 pounds. That is a real number from its own population, and publishing it is more than most of this field does. Read it as what the program produced, not as a version of SURMOUNT-1.

HumeCare does not publish a milligram figure anywhere, including at checkout — the site says the provider sets the final dose. So "smaller" is not quantified, and there is no way to compare its dosing to a standard ladder before you enrol. If dose matters to your decision, get the milligrams in writing first. Our tirzepatide dosage chart sets out what the standard ladder looks like.

What the $199 includes

The bundle is genuinely broad for the price: the compounded medication if prescribed, clinical visits, behavioral coaching, and access to the Hume system — muscle-and-fat tracking plus a dosing tracker. HumeCare+ is the GLP-1 arm of Hume Health, the body-composition scale company, and that heritage is the most interesting thing about the offer.

Tracking fat mass and lean muscle separately addresses something the scale cannot show. Loss of lean mass alongside fat is a recognized concern with GLP-1 treatment, and a program that reads body composition weekly can at least see it happening. Whether it changes your outcome depends on what the clinician does with the reading.

Billing is monthly with no minimum term, which stands out in a market that routinely asks for a three-, six- or twelve-month prepay to reach its headline rate. HumeCare's $199 is the monthly rate, not an annualised one — there is no cheaper tier waiting behind a year's commitment, and no prepay arithmetic to unpick.

The program is available in every U.S. state except Alabama, Louisiana and Mississippi.

What is not published

Three gaps are worth knowing before you pay.

No pharmacy is named, and no 503A or 503B classification is stated. No milligram figure appears at any point, including checkout. And the terms reserve a non-refundable clinical consultation fee charged at enrollment and at each refill without stating its size, plus the right to charge more for certain dosages or formulations — so $199 is a floor rather than a ceiling. Ask what the consultation fee is before you start.

The money-back language also deserves reading twice: the marketing promises 180 days, while the contract offers 90, pays only if you achieved no measurable weight loss at all, excludes the consultation fee, and disqualifies anyone who has used a GLP-1 before.

The compounded-versus-brand distinction

HumeCare dispenses compounded tirzepatide, not Zepbound or Mounjaro. Compounded tirzepatide is pharmacy-prepared, is not an FDA-approved finished drug, is not a generic of the brand, and was not the product studied in the pivotal trials. HumeCare states plainly on the page that it has no affiliation with Eli Lilly, the only U.S. source of FDA-approved tirzepatide — a disclosure many competitors leave out.

The bottom line

$199 a month, billed monthly, nothing locked in, and a body-composition analyzer shipped with the medication. Set against that: it is a microdose protocol, the milligrams are never published, the pharmacy is never named, and a consultation fee of unstated size sits on top at every refill. If you want lower-dose treatment with weekly muscle-and-fat readings and no commitment, it is a genuinely distinctive offer. If you want the doses the trials tested, this is not the program for that, and you should compare it against standard-dose programs on published monthly prices rather than against its headline.